Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Colorectal Neoplasms 5 Neoplasms 4 Stomach Neoplasms 3 Malnutrition 3 Lung Neoplasms 3 Diarrhea 3 Uterine Cervical Neoplasms 2 Mucositis 2 Inflammation 2 Enteritis 2 Chalazion 2 Carcinoma, Hepatocellular 2 Thyroid Neoplasms 1 Squamous Intraepithelial Lesions 1 Smoldering Multiple Myeloma 1 Radiation Injuries 1 Psychological Well-Being 1 Psoriasis Vulgaris 1 Polycystic Ovary Syndrome 1 Periampullary Carcinoma Nos 1 Pelvic Neoplasms 1 Pelvic Inflammatory Disease 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Neoplasms, Second Primary 1 Muscle Invasive Bladder Cancer (MIBC) 1 Multiple Myeloma 1 Motor Activity 1 Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Carboplatin 784 Pemetrexed 607 Cisplatin 545 Paclitaxel 491 pembrolizumab 464 Docetaxel 440 Gemcitabine 328 Erlotinib Hydrochloride 307 Radiotherapy 258 Nivolumab 244 Bevacizumab 233 osimertinib 178 Drug Therapy 164 durvalumab 157 atezolizumab 135 Gefitinib 134 Radiosurgery 133 Vinorelbine 111 Cetuximab 97 130-nm albumin-bound paclitaxel 94 Ipilimumab 86 Magnetic Resonance Spectroscopy 84 Taxes 79 Surgical Procedures, Operative 74 Afatinib 68 Albumin-Bound Paclitaxel 66 Specimen Handling 61 Etoposide 61 Cyclophosphamide 60 tislelizumab 59

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Probiotics × Clear all

NCT01465802 2019-01-09

ARCHER 1042

Pfizer

Phase 2 Completed

236 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡